Skip to main content

Dr. Jack H. Florin, MD

Neurology (Neurology Physician)

  • Medicare participating

At a glance

Years since graduation
56
In the NPI registry since
2005
Medicare patients seen, 2024
441

Licensed in California since 1974, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1970Medical school: Albert Einstein College of Medicine of Yeshiva University
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology Physician primary
    CA license G26561 (first issued 1974; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Neurology per capita by county →

Medicare patients and services

Medicare patients, 2024
441
Services billed
26,238
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, onabotulinumtoxina, 1 unit22,70041
Injection, eptinezumab-jjmr, 1 mg14,40032
Established patient office or other outpatient visit, 30-39 minutes561325
Established patient office or other outpatient visit, 20-29 minutes332163
New patient office or other outpatient visit, 45-59 minutes151151
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less13042
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face11034
Established patient office or other outpatient visit, 40-54 minutes4540
Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box3212
Injection of anesthetic agent and/or steroid into upper neck and back of head nerve3211

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 5 payments worth $820 in total to this clinician.

By company
Lilly USA, LLC$700
Novartis Pharmaceuticals Corporation$64.31
Axsome Therapeutics, Inc.$29.77
Telix Pharmaceuticals$25.43
By type
Compensation for services other than consulting (speaking, faculty)$700
Food and Beverage$120

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 13, 2025Lilly USA, LLC
Nov 13, 2025
Compensation for services other than consulting (speaking, faculty)$700

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $3,125,094 in research payments for these studies, mostly to the institutions running them.

  • An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
    Novartis Pharmaceuticals Corporation
  • A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension …
    Novartis Pharmaceuticals Corporation
  • A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
    Novartis Pharmaceuticals Corporation
  • A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
    Genentech, Inc.
  • Study to Evaluate SAGE-324 in Participants With Essential Tremors
    Sage Therapeutics, LLC
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
    E.r. Squibb & Sons, L.l.c.
  • A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
    Novartis Pharmaceuticals Corporation
  • A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
    Sage Therapeutics, LLC
  • A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
    Novartis Pharmaceuticals Corporation
  • A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
    Ipsen Innovation · Active, not recruiting · NCT06047457

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Fullerton

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 13, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1912990656. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.